Researchers at the Aventis Cambridge Genomics Center are in talks to buy a broad set of siRNAs from Dharmacon and are mulling over taking a license to Akceli’s reverse transfection siRNA microarray technology to bolster their efforts to identify genes that confer sensitivity or resistance to the breast and lung cancer drug Taxotere, RNAi News has learned.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.